Abstract
Octreotide is the cornerstone of perioperative management of neuroendocrine tumours, but there is no universal agreement on the optimal regimen. This article discusses the evidence for its use during different parts of the perioperative pathway.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: British journal of hospital medicine (London, England : 2005)
Paper Title
Journal
Date
